Helmedix

Helmedix

Developing novel therapies for autoimmune and inflammatory diseases such as rheumatoid arthritis, colitis, psoriasis and multiple sclerosis.

Launch date
Employees
Market cap
-
Enterprise valuation
AUD5—8m (Dealroom.co estimates Feb 2013.)
Melbourne Victoria (HQ)
  • Edit
DateInvestorsAmountRound

AUD1.3m

Seed
Total FundingAUD1.3m

Recent News about Helmedix

Edit